1	TITLE PAGE
2	
3	Type of article: Research article
4	
5	Full-length title:
6	Culture and identification of a "Deltamicron" SARS-CoV-2 in a three cases cluster in
7	southern France
8	
9	Short title (for the running head): Emergence of a SARS-CoV-2 Delta/Omicron
10	recombinant
11	
12	Author list: Philippe COLSON <sup>1,2,3</sup> *, Pierre-Edouard FOURNIER <sup>1,2,4</sup> , Jeremy
13	DELERCE <sup>1</sup> , Matthieu MILLION <sup>1,2,3</sup> , Marielle BEDOTTO <sup>1</sup> , Linda HOUHAMDI <sup>1</sup> ,
14	Nouara YAHI <sup>5</sup> , Jeremy BAYETTE <sup>6</sup> , Anthony LEVASSEUR <sup>1,2</sup> , Jacques FANTINI <sup>5</sup> ,
15	Didier RAOULT <sup>1,2</sup> , Bernard LA SCOLA <sup>1,2,3</sup> *
16	Affiliations: <sup>1</sup> IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille,
17	France; <sup>2</sup> Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Microbes
18	Evolution Phylogeny and Infections (MEPHI), 27 boulevard Jean Moulin, 13005 Marseille,
19	France; <sup>3</sup> Assistance Publique-Hôpitaux de Marseille (AP-HM), 264 rue Saint-Pierre, 13005
20	Marseille, France; <sup>4</sup> Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD),
21	Vecteurs – Infections Tropicales et Méditerranéennes (VITROME), 27 boulevard Jean
22	Moulin, 13005 Marseille, France; <sup>5</sup> Aix-Marseille Université, INSERM UMR S 1072, 51
23	boulevard Pierre Dramard, 13015 Marseille, France; <sup>6</sup> LBM Inovie Labosud, 90 rue Nicolas
24	Chedville, 34070, Montpellier, France.

**\* Corresponding author:** Bernard La Scola, IHU Méditerranée Infection, 19-21 boulevard NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 26 Jean Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email:
- 27 bernard.la-scola@univ-amu.fr; Philippe Colson, IHU Méditerranée Infection, 19-21
- 28 boulevard Jean Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732
- 29 402; email: philippe.colson@univ-amu.fr
- 30 Key words: SARS-CoV-2; recombinant; variant; lineage; Delta; Omicron; Deltamicron;
- 31 epidemic
- 32 Word counts: abstract, 180; text, 2,364
- 33 Figures: 3; Table: 1; References: 47
- 34
- 35

2	6
J	υ

# ABSTRACT

37

38 Multiple SARS-CoV-2 variants have successively, or concommitantly spread 39 worldwide since summer 2020. A few co-infections with different variants were reported and 40 genetic recombinations, common among coronaviruses, were reported or suspected based on 41 co-detection of signature mutations of different variants in a given genome. Here we report 42 three infections in southern France with a Delta 21J/AY.4-Omicron 21K/BA.1 "Deltamicron" 43 recombinant. The hybrid genome harbors signature mutations of the two lineages, supported 44 by a mean sequencing depth of 1,163-1,421 reads and mean nucleotide diversity of 0.1-0.6%. 45 It is composed of the near full-length spike gene (from codons 156-179) of an Omicron 21K/BA.1 variant in a Delta 21J/AY.4 lineage backbone. Importantly, we cultured an isolate 46 47 of this recombinant and sequenced its genome. It was observed by scanning electron 48 microscopy. As it is misidentified with current variant screening qPCR, we designed and 49 implemented for routine diagnosis a specific duplex qPCR. Finally, structural analysis of the 50 recombinant spike suggested its hybrid content could optimize viral binding to the host cell 51 membrane. These findings prompt further studies of the virological, epidemiological, and 52 clinical features of this recombinant.

53

5	5
J	J

56

# TEXT

# 57 Introduction

58 The current SARS-CoV-2 pandemic has highlighted since the summer of 2020 the 59 successive or concomittant emergence of numerous viral variants, each causing a specific epidemic.<sup>1-3</sup> Some of these variants spread to become pandemic while others remained 60 61 epidemic in a restricted geographical area. The variants characterized so far have been shaped 62 by nucleotide substitutions, insertions or deletions. However, another major evolutionary 63 mechanism of RNA viruses is genetic recombination, which is very common among 64 coronaviruses.<sup>4-8</sup> It requires co-infection of the same host cell by two viruses, which may be two distinct mutants or variants.<sup>9</sup> Therefore, the frequency of creation of recombinants 65 66 between two variants depends on the duration of their co-circulation, on the time until viral 67 clearance, and on the number of people exposed to both viruses. Co-infections with two variants were reported including recently with SARS-CoV-2 Delta and Omicron variants.<sup>10-13</sup> 68 69 Furthermore, genetic recombinations were reported or suspected, based on the concurrent detection in consensus genomes of signature mutations of different mutants or variants.<sup>10,12,14-</sup> 70  $^{24}$  A study detected up to 1,175 (0.2%) putative recombinant genomes among 537,360 71 72 genomes and estimated that up to 5% SARS-CoV-2 having circulated in the USA and UK 73 could be recombinants.<sup>16</sup>

Two pandemic variants, Delta and Omicron 21K (Nextclade classification<sup>25,26</sup>)/BA.1
(Pangolin classification<sup>27</sup>), recently succeeded each other as the predominant viruses but cocirculated for a period of several weeks, creating conditions for co-infections and
subsequently recombinations. This period spanned between December 27<sup>th</sup>, 2021 and
February 14<sup>th</sup>, 2022 in our geographical area, as assessed by our SARS-CoV-2 genotypic
surveillance based on variant-specific qPCR and next-generation genomic sequencing.<sup>3,28,29</sup> In

80	January 2022, genomes harboring mutations from both Delta and Omicron 21K/BA.1 variants
81	were reported in Cyprus but it was questioned whether sequences might have resulted from
82	contamination. <sup>23</sup> Still, 15 genomes as of 27/02/2022 being hybrids of these two variants and
83	highly similar between each other were reported since February 2022 (https://github.com/cov-
84	lineages/pango-designation/issues/444). We herein report three infections by a recombinant
85	SARS-CoV-2 Delta 21K/AY.4-Omicron 21K/BA.1 whose genome is highly similar to the 15
86	previously reported genomes and the isolation of the recombinant virus from one of the
87	patients.
88	

# 89 Materials and methods

90 Nasopharyngeal samples were collected from two patients in our university hospital 91 institute (Méditerranée Infection; https://www.mediterranee-infection.com/) and tested for 92 SARS-CoV-2 infection by real-time reverse transcription-PCR (qPCR) as previously described.<sup>3,28,29</sup> The third patient was sampled in a private medical biology laboratory in 93 94 southern France (Inovie Labosud, Montpellier, France). qPCR assays that screen for SARS-95 CoV-2 variants were performed as recommended by French public health authorities 96 (https://www.data.gouv.fr/fr/datasets/donnees-de-laboratoires-pour-le-depistage-indicateurs-97 sur-les-mutations/). In our center this included the detection of spike mutation among which 98 K417N (Thermo Fisher Scientific, Waltham, USA), combined with testing with the TaqPath 99 COVID-19 kit (Thermo Fisher Scientific) that target viral genes ORF1, N (nucleocapsid) and S (spike), as previously reported.<sup>3,28,29</sup> The private medical laboratory used the ID SARS-100 101 CoV-2/VOC Revolution Pentaplex assay (ID Solutions, Grabels, France) that detects spike 102 mutations K417N, L452R, and E484K (Pentaplex assay, ID Solution, France). 103 SARS-CoV-2 genomes were sequenced in the framework of genomic surveillance implemented since February 2020<sup>3</sup> in our institute. Next-generation sequencing was 104

105	performed	with the	Illumina	COVID-seq	protocol	on the NovaSec	g 6000 instrument	(Illumina

- 106 Inc., San Diego, CA, USA) or with the Oxford Nanopore technology (ONT) on a GridION
- 107 instrument (Oxford Nanopore Technologies Ltd., Oxford, UK) combined with prior multiplex
- 108 PCR amplification according to the ARTIC procedure (https://artic.network/), as previously
- 109 described,<sup>3,28</sup> with the ARTIC nCoV-2019 Amplicon Panel v4.1 of primers (IDT, Coralville,
- 110 IA, USA). Then, sequence read processing and genome analysis were performed as
- 111 previously described.<sup>3,28</sup> Briefly, for Illumina NovaSeq reads, base calling was performed
- 112 with the Dragen Bcl Convert pipeline [v3.9.3;
- 113 https://emea.support.illumina.com/sequencing/sequencing\_software/bcl-convert.html
- (Illumina Inc.)], mapping was performed with the bwa-mem2 tool (v. 2.2.1;
- 115 https://github.com/bwa-mem2/bwa-mem2) on the Wuhan-Hu-1 isolate genome (GenBank
- 116 accession no. NC\_045512.2) then cleaned with Samtools (v. 1.13; https://www.htslib.org/),
- 117 variant calling was carried out with freebayes (v. 1.3.5;
- 118 https://github.com/freebayes/freebayes) and consensus genomes were built using Bcftools (v.
- 119 1.13; https://samtools.github.io/bcftools/bcftools.html). ONT reads were processed with the
- 120 ARTIC-nCoV-bioinformaticsSOP pipeline v1.1.0 (https://github.com/artic-
- 121 network/fieldbioinformatics). Nucleotide and amino acid changes relatively to the Wuhan-
- 122 Hu-1 isolate genome were obtained using the Nextclade tool
- 123 (https://clades.nextstrain.org/).<sup>25,26</sup> Nextstrain clades and Pangolin lineages were determined
- 124 using the Nextclade web application (https://clades.nextstrain.org/)<sup>25,26</sup> and the Pangolin tool
- 125 (https://cov-lineages.org/pangolin.html),<sup>27</sup> respectively. Genome sequences described here
- 126 were deposited in the GenBank sequence database (https://www.ncbi.nlm.nih.gov/genbank/)<sup>30</sup>
- 127 (OM990851, OM990852, OM991095, OM991295), and on the IHU Méditerranée Infection
- 128 website (https://www.mediterranee-infection.com/sars-cov-2-recombinant/). The Simplot
- 129 software (https://sray.med.som.jhmi.edu/SCRoftware/SimPlot/)<sup>31</sup> was used for recombination

analysis. Phylogeny was reconstructed by the IQTree (v2.1.3; http://www.iqtree.org/)<sup>32</sup> or 130 MEGA X<sup>33</sup> (v10.2.5; https://www.megasoftware.net/) tools and visualized with MEGA X 131 132 after sequence alignment with MAFFT (https://mafft.cbrc.jp/alignment/server/).<sup>34</sup> As 133 phylogenetic analysis can hardly applies to sequences that have different evolutionary 134 histories, we built two separate trees, a first one for the regions classified as of the Delta 135 21J/AY.4 variant (positions 1-22,128 and 25,519-29,903 in reference to the genome of the 136 Wuhan-Hu-1 isolate), and a second one for the regions classified as of the Omicron 21K/BA.1 137 variant (positions 22,129-25,519). The 10 genomes the closest genetically to these fragments of the genome obtained here were selected through a BLAST<sup>35</sup> search among genomes of the 138 139 Delta 21J/AY.4 and Omicron 21K/BA.1 variants in the sequence database of our institute that 140 contains approximately 50,000 SARS-CoV-2 genomes; then, they were incorporated in the 141 phylogeny together with the genome of the Wuhan-Hu-1 isolate. As a matter of fact, it should 142 not be acceptable to make a phylogenetic tree based on concatenation of sequences from 143 different origin. 144 SARS-CoV-2 culture isolation was performed by inoculating 200 µL of respiratory 145 sample on Vero E6 cells as previously described.<sup>36</sup> Cytopathic effect was observed by

146 inverted microscopy. Viral particles were visualized in the culture supernatant by scanning

147 electron microscopy with a SU5000 microscope (Hitachi High-Technologies Corporation,

148 Tokyo, Japan), as previously described.<sup>37</sup>

Structural predictions of the spike protein were performed as previously
described.<sup>28,38,39</sup> Briefly, amino acid changes were introduced in the framework of a complete
14-1,200 structure of the original SARS-CoV-2 20B spike and missing amino acids were
incorporated with the Robetta protein structure prediction tool (https://robetta.bakerlab.org/)
before energy minimization through the Polak-Ribière algorithm.
A in house duplex qPCR assay specific of the SARS-CoV-2 recombinant was

- designed that targets the genomes of the Delta 21J [targeted mutation: A11201G in the Nsp6
- 156 gene (corresponding to amino acid substitution T77A)] and the Omicron 21K/BA.1 [targeted
- 157 mutations: A23040G, G23048A, A23055G in the spike gene (Q493R, G496S, Q498R)]
- variants. The sequences of the primers and probes (in 5'-3' orientation) are as follows: (i) for
- 159 the Delta 21J-targeting system: forward primer, CTGCTTTTGCAATGATGTTTGT; reverse
- 160 primer, TACGCATCACCCAACTAGCA; probe, 6FAM-
- 161 CTTGCCGCTGTAGCTTATTTTAAT (primers and probe concentrations in the mix were
- 162 200 nM and 150 nM, respectively); (ii) for the Omicron 21K/BA.1-targeting system: forward
- 163 primer, CCTTGTAATGGTGTTGAAGGTTTT; reverse primer,
- 164 CTGGTGCATGTAGAAGTTCAAAAG; probe, 6VIC-
- 165 TTTACGATCATATAGTTTCCGACCC (primers and probe concentrations in the mix were
- 166 250 nM and 200 nM, respectively).
- 167 This study was approved by the ethics committee of University Hospital Institute168 Méditerranée Infection (No. 2022-001).
- 169
- 170 Results

171 The three case-patients were SARS-CoV-2-diagnosed on nasopharyngeal samples 172 collected in February 2022. Cycle threshold values (Ct) of diagnostic qPCR were between 20-173 21. The patients were below 40 years of age. They resided in southern France and did not 174 travel abroad recently. They presented mild respiratory symptoms. Two were vaccinated 175 against SARS-CoV-2 (with two or three doses administered). Variant screening qPCR for the 176 2 samples collected in our institute showed positivity for the K417N mutation while the 177 TaqPath COVID-19 kit provided positive signals for all three genes targeted (ORF1, S, and 178 N). The third sample showed positivity for the K417N mutation and negativity for the L452R 179 and E484K mutations. Thus, overall, qPCR carried out on the three samples were indicative

180 of a Omicron variant.

181 The three viral genomes [GenBank Accession no. OM990851, OM990852, 182 OM991095 (https://www.ncbi.nlm.nih.gov/genbank/)<sup>30</sup>; available on the IHU Méditerranée 183 Infection website (https://www.mediterranee-infection.com/sars-cov-2-recombinant/)] were 184 hybrids of Delta 21J/AY.4 and Omicron 21K/BA.1 variant genomes (Figures 1a, b, c; Table 185 1). At positions harboring mutations compared to the genome of the Wuhan-Hu-1 isolate, 186 mean sequencing depth was between 1,163-1,421 reads and mean prevalence of the 187 majoritary nucleotide was between 99.4-99.9% (with minimum values between 80.3-98.7%), 188 ruling out the concurrent presence of two variants in the samples either due to co-infection or 189 to contamination. In this SARS-CoV-2 recombinant, most of the spike gene was replaced in a 190 Delta 21J/AY.4 matrix by an Omicron 21K/BA.1 sequence (Figures 1a, b, c). Indeed, the recombination sites were located between nucleotide positions 22,034 and 22,194 for the first 191 192 one, and between nucleotide positions 25,469 and 25,584 for the second one. These regions 193 corresponds to amino acids 158 to 211 of the spike protein and to amino acids 26 to 64 of the 194 ORF3a protein whose gene is contiguous to the spike gene. The Simplot recombination 195 analysis tool provided congruent results. 196 Genomes from two of the three patients were identical and clustered in the 197 phylogenetic analysis (Figures 1d, e) despite no epidemiological link was documented 198 between these two patients. The third genome exhibited 5 nucleotide differences. 199 Phylogenetic analyses showed that most of the recombinant genomes was most closely related 200 to Delta 21J/AY.4 variant genomes identified in our institute, while the region spanning a

201 large part of their spike gene was most closely related to Omicron 21K/BA.1 variant genomes
202 identified in our institute.

203 The respiratory sample from which the first recombinant genome was obtained was
204 inoculated on Vero E6 cells the day following recombinant identification, and cytopathic

205 effect was observed after 4 days (Figures 2a, b; collection of strains of IHU Méditerranée 206 Infection, no. IHUMI-6070VR). The same day, supernatant was collected and next-generation 207 genome sequencing was performed using Nanopore technology on a GridION instrument 208 after PCR amplification with Artic primers, which allowed obtaining the genome sequence of 209 the viral isolate 8 h later [GenBank Accession no. OM991295] (https://www.ncbi.nlm.nih.gov/genbank/)<sup>30</sup>; available on the IHU Méditerranée Infection 210 211 website (https://www.mediterranee-infection.com/sars-cov-2-recombinant/)]. At mutated 212 positions compared to the Wuhan-Hu-1 isolate genome, mean sequencing depth was 2,771 213 reads and mean prevalence of the majoritary nucleotide was 99.1% (minimum, 95.1%), and 214 the consensus genome was identical to that obtained from the respiratory sample, showing 215 unambiguously that the virus isolated was the Delta 21J/AY.4-Omicron 21K/BA.1 216 recombinant. Finally, viral particles were observed in the culture supernatant by scanning 217 electron microscopy with a SU5000 microscope within minutes after supernatant collection 218 (Figure 2c).

219 The overall structure of the recombinant spike protein was predicted (Figures 3a-c). 220 When superimposed with the spike of the Omicron 21K/BA.1 variant, the main structural 221 changes were located in the N-terminal domain (NTD). In this region, the surface of the 222 recombinant spike protein is enlarged, flattened, and more electropositive, a property that is 223 characteristic of the Delta 21J/AY.4 NTD (Figure 3c). In the initial interaction of the virus 224 with the plasma membrane of the host cells, the NTD is attracted by lipid rafts, which provides an electronegative landing platforms for the spike.<sup>38,39</sup> Thus, an increase in the 225 226 electrostatic surface of the NTD is expected to accelerate the binding of the virus to lipid rafts, which may confer a selective kinetic advantage against virus competitors.<sup>38</sup> The receptor 227 binding domain (RBD) of the recombinant is clearly inherited from the Omicron 21K/BA.1 228 229 variant (Figure 3c). The consequence is also an increase in the electrostatic surface potential

of the RBD, which may facilitate the interaction with the electronegative interface of the
ACE-2 cellular receptor. Overall, this structural analysis suggests that the recombinant virus
could have been selected on the basis of kinetic properties conferred by a convergent increase
of the electrostatic potential of both the NTD and the RBD, together with an enlargement of
the NTD surface, all features that suggest an optimization of virus binding to the host cell
membrane.

236 Currently used qPCR screening assays were not able to discriminate this Delta 237 21J/AY.4-Omicron 21K/BA.1 recombinant and the Omicron 21K/BA.1 variant because the 238 Delta variant signature mutation detected is absent from the recombinant genome. Therefore, 239 we attempted to promptly implement a specific qPCR assay that could be used to detect the 240 recombinant for routine diagnosis use. This was achieved in one day by selecting qPCR 241 systems from our toolbox of dozens of in house qPCR systems that were designed since the 242 emergence of the first variant during summer 2020 to specifically target SARS-CoV-2 variants or mutants.<sup>3,40</sup> Two systems that target either the Delta 21J variant or the Omicron 243 244 BA.1 variant were combined in a duplex qPCR that can screen for the recombinant. In 245 preliminary assessment, both tested recombinant-positive samples were positive for the Delta 246 21J and Omicron BA.1 targets. In addition, 7 Delta non-21J-positive samples were negative 247 for both targets, 4 Delta 21J-positive samples were positive for the Delta 21J target but 248 negative for the Omicron BA.1 target, and 3 Omicron BA.1-positive samples were negative 249 for the Delta 21J target but positive for the Omicron BA.1 target.

250

#### 251 Discussion

It is increasingly demonstrated that the genomes of most biological entities, whatever their level of complexity, are mosaics of sequences from various origins.<sup>41-45</sup> The present observations show us in real life the recombination potential of SARS-CoV-2, already largely

established for other coronaviruses.<sup>4-6,8,46</sup> and reported or suspected for SARS-CoV-2.<sup>10,12,14-24</sup> 255 256 SARS-CoV-2 recombinations were difficult to spot when only genetically very similar 257 viruses were circulating, as was the case in Europe during the first epidemic episode with 258 mutants derived from the Wuhan-Hu-1 virus. The increasing genetic diversity of SARS-CoV-259 2, the tremendous number of infections at global and national levels, and the unprecedented global effort of genomic sequencing (https://covariants.org/per-country),<sup>3,25,47</sup> raised the 260 261 probability of detecting recombinants. Such observations will probably make it possible in the 262 short or medium term to assess the recombination rate of SARS-CoV-2, whether there are 263 recombination hotspots, and to what extent recombinations between different variants can 264 generate new viable, and epidemic variants. This questions on the impact of recombinations 265 on viral replication and transmissibility, and on clinical severity, as well as on the virus ability 266 to escape neutralizing antibodies elicited by vaccines or a previous infection. In this view, 267 culture isolation of SARS-CoV-2 recombinants as was carried out here for the first time to 268 our knowledge is of primary importance. This variant mentioned recently has no known 269 epidemic potential. This will allow studying their phenotypic properties, among which their 270 replicative capacity in various cell lines, their sensitivity to antibodies, or their genetic 271 evolution *in vitro*. Concurrently, a high level of genomic surveillance must be maintained in 272 order to detect and characterize all recombination events and circulating recombinants, which 273 is a critical scientific and public health issue.

- 274
- 275

#### 276 Acknowledgments

277 We are very grateful to Clio Grimaldier, Rita Zgheib, Claudia Andrieu, Ludivine Bréchard,

278 Raphael Tola, Anthony Fontanini, and Jacques Bou Khalil for their technical help.

279 Author contributions

280 Study conception and design: Philippe Colson, Pierre-Edouard Fournier, Jacques Fantini, 281 Didier Raoult, Bernard La Scola. Materials, data and analysis tools: Philippe Colson, Pierre-282 Edouard Fournier, Jeremy Delerce, Matthieu Million, Marielle Bedotto, Linda Houhamdi, 283 Nouara Yahi, Jeremy Bayette, Jacques Fantini. Data analyses: Philippe Colson, Pierre-284 Edouard Fournier, Jeremy Delerce, Marielle Bedotto, Anthony Levasseur, Jacques Fantini, 285 Didier Raoult, Bernard La Scola. Writing of the first draft of the manuscript: Philippe Colson, 286 Jacques Fantini, and Pierre-Edouard Fournier. All authors read, commented on, and approved 287 the final manuscript. 288 Funding 289 This work was supported by the French Government under the "Investments for the Future" 290 program managed by the National Agency for Research (ANR), Méditerranée-Infection 10-291 IAHU-03; by Région Provence Alpes Côte d'Azur and European funding FEDER PRIMMI 292 (Fonds Européen de Développement Régional-Plateformes de Recherche et d'Innovation 293 Mutualisées Méditerranée Infection), FEDER PA 0000320 PRIMMI; by Hitachi High-294 Technologies Corporation, Tokyo, Japan; and by the French Ministry of Higher Education, 295 Research and Innovation (ministère de l'Enseignement supérieur, de la Recherche et de 296 l'Innovation) and the French Ministry of Solidarity and Health (Ministère des Solidarités et de 297 la Santé). 298 **Data availability** 299 The dataset generated during the current study is available from the GenBank database (https://www.ncbi.nlm.nih.gov/genbank/)<sup>30</sup> (GenBank Accession no. OM990851, OM990852, 300

301 OM991095, OM991295) and from the IHU Méditerranée Infection website

302 (https://www.mediterranee-infection.com/sars-cov-2-recombinant/).

#### **303** Conflicts of interest

304 Didier Raoult has a conflict of interest as having been a consultant for Hitachi High-

305	Technologies Corporation, Tokyo, Japan from 2018 to 2020. He is a scientific board member
306	of Eurofins company and a founder of a microbial culture company (Culture Top). All other
307	authors have no conflicts of interest to declare. Funding sources had no role in the design and
308	conduct of the study; collection, management, analysis, and interpretation of the data; and
309	preparation, review, or approval of the manuscript.
310	Ethics
311	This study has been approved by the ethics committee of the University Hospital Institute
312	Méditerranée Infection (No. 2022-001). Access to the patients' biological and registry data
313	issued from the hospital information system was approved by the data protection committee

- 314 of Assistance Publique-Hôpitaux de Marseille (APHM) and was recorded in the European
- 315 General Data Protection Regulation registry under number RGPD/APHM 2019-73.

017		DEFEDENCES
317		REFERENCES
318	1.	Lemey P, Ruktanonchai N, Hong SL, et al. Untangling introductions and persistence in
319		COVID-19 resurgence in Europe. Nature. 2021;595:713-717.
320	2.	Hodcroft EB, Zuber M, Nadeau S, et al Emergence and spread of a SARS-CoV-2
321		variant through Europe in the summer of 2020. Nature. 2021;595:707-712.
322	3.	Colson P, Fournier PE, Chaudet H, et al. Analysis of SARS-CoV-2 variants from
323		24,181 patients exemplifies the role of globalization and zoonosis in pandemics. Front
324		Microbiol. 2022b;12:786233.
325	4.	Lai MMC. Recombination in large RNA viruses: Coronaviruses. Semin Virol.
326		1996;7:381-388.
327	5.	Zhang Y, Li J, Xiao Y, et al. Genotype shift in human coronavirus OC43 and
328		emergence of a novel genotype by natural recombination. J Infect. 2015;70:641-50.
329	6.	Xiao Y, Rouzine IM, Bianco S, et al. RNA recombination enhances adaptability and is
330		required for virus spread and virulence. Cell Host Microbe. 2017;22:420.
331	7.	So RTY, Chu DKW, Miguel E, et al. Diversity of dromedary camel coronavirus
332		HKU23 in African camels revealed multiple recombination events among closely
333		related betacoronaviruses of the subgenus Embecovirus. J Virol. 2019;93:e01236-19.
334	8.	Gribble J, Stevens LJ, Agostini ML, et al. The coronavirus proofreading
335		exoribonuclease mediates extensive viral recombination. PLoS Pathog.
336		2021;17(1):e1009226.
337	9.	Bentley K, Evans DJ. Mechanisms and consequences of positive-strand RNA virus
338		recombination. J Gen Virol. 2018;99:1345-1356.
339	10.	Jackson B, Boni MF, Bull MJ, et al. Generation and transmission of interlineage
340		recombinants in the SARS-CoV-2 pandemic. <i>Cell</i> . 2021:184:5179-5188 e8

- 11. Francisco RDS Jr, Benites LF, Lamarca AP, et al. Pervasive transmission of E484K and
- 342 emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two
- different lineages in Rio Grande do Sul, Brazil. *Virus Res.* 2021;296:198345.
- 12. Taghizadeh P, Salehi S, Heshmati A, et al. Study on SARS-CoV-2 strains in Iran
- 345 reveals potential contribution of co-infection with and recombination between different
- 346 strains to the emergence of new strains. *Virology*. 2021;562:63-73.
- 13. Rockett, JD, Mailie G, Eby MS, et al. Co-infection with SARS-CoV-2 Omicron and
- 348 Delta Variants revealed by genomic surveillance. *medRxiv* 2022; 2022.02.13.22270755;
- 349 doi: https://doi.org/10.1101/2022.02.13.22270755.
- 350 14. Yi H. 2019 Novel coronavirus is undergoing active recombination. *Clin Infect Dis.*351 2020;71:884-887.
- 352 15. Yeh TY, Contreras GP. Emerging viral mutants in Australia suggest RNA
- recombination event in the SARS-CoV-2 genome. *Med J Aust.* 2020;213:44-44.e1.
- 16. VanInsberghe D, Neish AS, Lowen AC, Koelle K. Recombinant SARS-CoV-2
- 355 genomes are currently circulating at low levels. *bioRxiv* 2021;2020.08.05.238386. doi:
- 356 10.1101/2020.08.05.238386.
- 357 17. Gallaher WR. A palindromic RNA sequence as a common breakpoint contributor to
  358 copy-choice recombination in SARS-COV-2. *Arch Virol.* 2020;165:2341-2348.
- Haddad D, John SE, Mohammad A, et al. SARS-CoV-2: Possible recombination and
  emergence of potentially more virulent strains. *PLoS One*. 2021;16:e0251368.
- 361 19. Makarenkov V, Mazoure B, Rabusseau G, Legendre P. Horizontal gene transfer and
- recombination analysis of SARS-CoV-2 genes helps discover its close relatives and
  shed light on its origin. *BMC Ecol Evol*. 2021;21:5.
- 364 20. Varabyou A, Pockrandt C, Salzberg SL, Pertea M. Rapid detection of inter-clade
- 365 recombination in SARS-CoV-2 with Bolotie. *Genetics*. 2021;218:iyab074.

500 21. Leary S. Gaudieri S. Parker MD, et al. Generation of a novel SARS-C	JI SAK	ovel SAKS	-Cov-2 sud-
---	--------	-----------	-------------

- 367 genomic RNA due to the R203K/G204R variant in nucleocapsid: homologous
- 368 recombination has potential to change SARS-CoV-2 at both protein and RNA level.
- 369 *Pathog Immun.* 2021;6:27-49.
- 22. Lohrasbi-Nejad A. Detection of homologous recombination events in SARS-CoV-2.
- Biotechnol Lett. 2022 Jan 17:1–16. doi: 10.1007/s10529-021-03218-7. Epub ahead of
   print.
- 572 print.
- 373 23. Kreier F. Deltacron: the story of the variant that wasn't. *Nature*. 2022;602:19.
- 24. Ignatieva A, Hein J, Jenkins PA. Ongoing recombination in SARS-CoV-2 revealed
- through genealogical reconstruction. *Mol Biol Evol*. 2022;39:msac028.
- 376 25. Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment,
- 377 mutation calling and quality control for viral genomes. *Zenodo* 2021. doi:
- 378 https://doi.org/10.5281/zenodo.5607694.
- 379 26. Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen
  a80 evolution. *Bioinformatics*. 2018;34:4121-4123.
- 381 27. Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-
- 382 CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol*. 2020;5:1403-1407.
- 28. Colson P, Delerce J, Beye M, et al. First cases of infection with the 21L/BA.2 Omicron

384 variant in Marseille, France. *medRxiv* 2022a; 2022.02.08.22270495; doi:

- 385 https://doi.org/10.1101/2022.02.08.22270495.
- 386 29. Houhamdi L, Gautret P, Hoang VT, Fournier PE, Colson P, Raoult D. Characteristics of
- 387 the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-
- 388 December 2021. *J Med Virol*. 2022 Jan 20. doi: 10.1002/jmv.27613. Epub ahead of
- 389 print.

- 390 30. Sayers EW, Cavanaugh M, Clark K, Pruitt KD, Schoch CL, Sherry ST, Karsch-
- 391 Mizrachi I. GenBank. Nucleic Acids Res. 2022 Jan 7;50(D1):D161-D164.
- 392 31. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R,
- 393 Sheppard HW, Ray SC. Full-length human immunodeficiency virus type 1 genomes
- from subtype C-infected seroconverters in India, with evidence of intersubtype
- 395 recombination. J Virol. 1999 Jan;73(1):152-60.
- 396 32. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective
- 397 stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol.
- 398 2015 Jan;32(1):268-74. doi: 10.1093/molbev/msu300. Epub 2014 Nov 3. PMID:
- 399 25371430; PMCID: PMC4271533.
- 400 33. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary
- 401 Genetics Analysis across Computing Platforms. Mol Biol Evol. 2018 Jun 1;35(6):1547-
- 402 1549. doi: 10.1093/molbev/msy096. PMID: 29722887; PMCID: PMC5967553.
- 403 34. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple
- 404 sequence alignment based on fast Fourier transform. Nucleic Acids Res. 2002 Jul

405 15;30(14):3059-66. doi: 10.1093/nar/gkf436. PMID: 12136088; PMCID: PMC135756.

- 406 35. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search
- 407 tool. J Mol Biol. 1990;215:403-10.
- 408 36. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell
- 409 culture as a management tool for discharge of SARS-CoV-2 patients from infectious
- 410 disease wards. *Eur J Clin Microbiol Infect Dis*. 2020;39:1059-1061.
- 411 37. Colson P, Lagier JC, Baudoin JP, Bou Khalil J, La Scola B, Raoult D. Ultrarapid
- 412 diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-
- 413 CoV-2. Eur J Clin Microbiol Infect Dis. 2020 Aug;39(8):1601-1603.

- 414 38. Fantini J, Yahi N, Azzaz F, Chahinian H. Structural dynamics of SARS-CoV-2 variants:
- 415 A health monitoring strategy for anticipating Covid-19 outbreaks. *J Infect*.
- 416 2021;83:197-206.
- 417 39. Fantini J, Yahi N, Colson P, Chahinian H, La Scola B, Raoult D. The puzzling
- 418 mutational landscape of the SARS-2-variant Omicron. *J Med Virol.* 2022 Jan 8. doi:
- 419 10.1002/jmv.27577. Epub ahead of print.
- 420 40. Bedotto M, Fournier PE, Houhamdi L, Colson P, Raoult D. Implementation of an in-
- 421 house real-time reverse transcription-PCR assay to detect the emerging SARS-CoV-2
- 422 N501Y variants. *J Clin Virol*. 2021;140:104868.
- 423 41. Raoult D. A viral grandfather: genomics in 2010 contradict Darwin's vision of
- 424 evolution. *Eur J Clin Microbiol Infect Dis.* 2011;30:935-6.
- 425 42. Merhej V, Raoult D. Rhizome of life, catastrophes, sequence exchanges, gene creations,
  426 and giant viruses: how microbial genomics challenges Darwin. *Front Cell Infect*
- 427 *Microbiol.* 2012;2:113.
- 428 43. Feschotte C, Gilbert C. Endogenous viruses: insights into viral evolution and impact on
  host biology. *Nat Rev Genet*. 2012;13:283-96.
- 430 44. Roux S, Enault F, Bronner G, Vaulot D, Forterre P, Krupovic M. Chimeric viruses blur
- the borders between the major groups of eukaryotic single-stranded DNA viruses. *Nat Commun.* 2013;4:2700.
- 433 45. Jacobs GS, Hudjashov G, Saag L, et al. Multiple deeply divergent Denisovan ancestries
  434 in Papuans. *Cell*. 2019;177:1010-1021.e32.
- 435 46. Liu X, Shao Y, Ma H, et al. Comparative analysis of four Massachusetts type infectious
- 436 bronchitis coronavirus genomes reveals a novel Massachusetts type strain and evidence
- 437 of natural recombination in the genome. *Infect Genet Evol.* 2013;14:29-38.

- 438 47. Hodcroft E. 2012. CoVariants: SARS-CoV-2 mutations and variants of interest.
- 439 Available from: https://covariants.org/.

441	FIGURE LEGEND
442	
443	Figure 1. Schematic of the SARS-CoV-2 Delta 21J/AY.4-Omicron 21K/BA.1
444	recombinant genome, and phylogenetic trees based on different regions of the
445	Deltamicron genome reflecting the origin of most of the viral genome from a Delta
446	21J/AY.4 variant and the origin of a region spanning a large part of the spike gene from
447	a Omicron 21K/BA.1 variant.
448	a: Map of the SARS-CoV-2 genome.
449	b: Schematic representation of parental and recombinant genomes.
450	c: Mutations in the three Delta 21J/AY.4-Omicron 21K/BA1 recombinant genomes. Adapted
451	from screenshots of the nextclade web application output (https://clades.nextstrain.org). <sup>25,26</sup>
452	Color codes for nucleotide mutations and are marked regions as follows: Green: U; yellow: G;
453	blue: C; red: A; grey: deletions or uncovered regions. Genomes are labelled with the
454	identifiers of the IHU Méditerranée Infection and the GenBank
455	(https://www.ncbi.nlm.nih.gov/genbank/) <sup>30</sup> sequence databases.
456	d, e: Phylogenetic trees based on different regions of the Deltamicron genomes showing the
457	origin of most of the viral genome from a Delta 21J/AY.4 variant (d) and the origin of a
458	region spanning a large part of the spike gene from a Omicron 21K/BA.1 variant (e). The 10
459	genomes the most similar genetically to these regions of the recombinant genomes obtained
460	here were selected from the sequence database of our institute through a BLAST <sup>35</sup> search,
461	then were incorporated in the phylogeny together with the genome of the Wuhan-Hu-1
462	isolate. Sequences are labelled with the identifiers of the IHU Méditerranée Infection and the
463	GenBank (https://www.ncbi.nlm.nih.gov/genbank/) <sup>30</sup> sequence databases.
464	

#### Figure 2. Microscopy images of the virus cytopathic effect (a, b) and of a viral particle 465

#### 466 (c) in culture of the SARS-CoV-2 Delta 21J/AY.4-Omicron 21K/BA.1 recombinant on

### 467 Vero E6 cells.

- 468 a. Absence of cytopathic effect (negative control: absence of virus); b. Cytopathic effect
- 469 observed 4 days post-inoculation on Vero E6 cells of the respiratory sample of the first patient
- 470 for whom the SARS-CoV-2 Delta 21J/AY.4-Omicron 21K/BA.1 recombinant was identified.
- 471 c. Scanning electron microscopy image was obtained with a SU5000 microscope (Hitachi
- 472 High-Technologies Corporation, Tokyo, Japan).

473

### 474 Figure 3. Schematic of the predicted structure of the spike protein of the SARS-CoV-2

# 475 Delta 21J/AY.4-Omicron 21K/BA.1 recombinant

- 476 a. Overall structure of the recombinant spike protein. The secondary structure is in grey,
- 477 mutated amino acids are in blue. NTD, N-terminal domain; RBD, receptor binding domain;
- 478 S1-S2, cleavage site.
- b. Superimposition of the secondary structure of the Omicron 21K/BA.1 variant (in cyan) and
- 480 recombinant (in red) spike proteins. NTD, N-terminal domain; RBD, receptor binding

481 domain.

- 482 c. Comparison of the electrostatic surface potential of the spike proteins in Delta 21J/AY.4
- 483 lineage, Omicron 21K/BA.1 variant, and in the recombinant. The color scale (negative in red,
- 484 positive in blue, neutral in white) is indicated. NTD, N-terminal domain; RBD, receptor
- 485 binding domain.

486

# **TABLE**

#### 488

#### 489 Table 1. Nucleotide and amino acid changes in the Deltamicron recombinant according to

490 their presence/absence in the Delta 21J/AY.4 lineage and the Omicron 21K/BA.1 variant.

491

SARS-CoV-2 genes or genome regions	Nucleotide changes	Amino acid changes	Present in the Delta 21J/AY.4 lineage	Present in the Omicron 21K/BA.1 variant	Present in the Delta 21J/AY.4- Omicron 21K/BA.1 recombinant
5UTR	G210U	/	Х		Х
5UTR	C241U	/	X	X	X
ORF1a	A1321C	E352D	<b>X</b> 7	<b>X7</b>	<u>X</u>
ORF1a	C3037U	/ /	X	X	X
ORF1a	C6402U	P2046L	<u>A</u>		<u>A</u> X
ORF1a	C7124U	P2287S	X		X
ORF1a	C7851U	A2529V	X		X
ORF1a	A8723G	I2820V	X7		<u>X</u>
ORF1a OPE1a	C8986U G9053U	/ V2930I	<u> </u>		X V
ORF1a	C10029U	T3255I	X	X	<u>A</u>
ORF1a	A11201G	T3646A	X		X
ORF1a	A11332G	/	X		X
ORF1b	C14407U	P314F / P314L	<b>X</b> 7	77	<u>X</u>
ORFIb	<u>C14408U</u>	P314F / P314L	X	Χ	X
ORF1b	G15451A	G662S	<u>л</u> Х		AX
ORF1b	C16466U	P1000L	X		X
ORF1b	C19220U	A1918V	X		X
S	C21618G	T19R	X		X
<u>S</u>	G21641U	A27S	X7		X
<u> </u>	C21846U	<u>1951</u>	X	<u>X</u>	X
S	GAGUUCA22028G	EFR156G	X		
S	AAUU22193A	NL211I	~	X	X
S	U22204UGAGCCAGAA	Ins214EPE		X	X
S	G22578A	G339D		X	X
S	UC22673CU	S371L		<u>X</u>	<u>X</u>
<u>s</u>	U22679C	S373P		X	X
S	G22813U	K417N		X	<u>A</u> X
S	U22882G	N440K		X	X
S	G22898A	G446S		X	X
S	G22992A	S477N		X	X
S	C22995A	T478K	X	X	X
<u> </u>	A23013C	E484A		X	X
S	G23048A	G496S		X	X
S	A23055G	Q498R		X	X
S	A23063U	N501Y		X	X
<u>S</u>	U23075C	Y505H		X	<u>X</u>
<u> </u>	C23202A	T547K	v	X	X
S	C23525U	H655Y	Δ	X	AX
S	U23599G	N679K		X	X
S	C23604A	P681H		X	X
<u>S</u>	C23854A	N764K		<u>X</u>	X
S	G23948U	D796Y		X	X
S	A2442411	0954H		X	<u>А</u> Х
S	U24469A	N969K		X	X
S	C24503U	L981F		X	X
S	C25000U	/		Х	X
ORF3a	C25667U	S92L			<u>X</u>
ORF3a	G25855U	D155Y	v		<u> </u>
ORF7a	U20707C	 V82A	<u>л</u> Х		<u></u> Х
ORF7a	C27752U	T120I	X		X
ORF7b	C27874U	T40I	X		X
ORF8	AGAUUUC28247A	DF119Del	<u>X</u>		X
Intergenic region	UA28270U	/	X		<u>X</u>
N	A28461G	D63G P202M	Xv		<u> </u>
N	G28916U	G215C	<u>А</u> Х		<u>л</u> Х
N	G29402U	D377Y	X		X
Intergenic region	G29540A	/			X
ORF10	G29645U				<u>X</u>
3UTR	G29742U	/	X		X

492 /, no change; Ins, insertion; Del, deletion; UTR, untranslated region; X, present. S gene region is indicated by a grey 493 background.

RNA-dependent RNA polymerase

<b>a.</b> Map of the SARS-CoV-2 genome	nsp1			3C-like prot	nsp7 einase nsp6	nsp9 nsp8 n	9 sp10	NTPase/helicas	e domain nsp15	Envelope glycopro	ORF7b ORF8 ORF7a ORF9b ORF7a ORF14	
			Predicted phosphoesterase						nsp16	Spike glycoprotein ORF3a		)
		nsp2	PLpro	nsp4	3CL					<u> </u>		
	0		5,000	10,0	.00		15,000		20,000	25,000 membrane gly	/coprotein 29,903	
											Nucleocapsid phosphprotein	

# b. Schematic of parental and recombinant genomes



#### C. Nucleotide mutations in the three Delta 21J AY.4 / Omicron 21K/BA1 recombinant genomes



d. Phylogeny based on the recombinant genomes excluding their Omicron 21K/BA.1 region

# **e.** Phylogeny based on the Omicron 21K/BA.1 region of the recombinant genomes

045512.2

S

THEODING STATE

HUCOVID-68496

IHUCOVID-67545

IHUCOVID-67554

IHUCOVID-67558

HUCOND 51559

HUCOVID-67566



Fig. 2







b.

